Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: Relationship to glycemia*

Blood glucose concentration and outcome of critical illness: The impact of diabetes*

(2009) Moritoki Egi et al.   CRITICAL CARE MEDICINE

Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine and American Society for Parenteral and Enteral Nutrition: Executive Summary*

(2009) Robert G. Martindale et al.   CRITICAL CARE MEDICINE

Endogenous Glucagon-Like Peptide-1 Slows Gastric Emptying in Healthy Subjects, Attenuating Postprandial Glycemia

(2009) Adam M. Deane et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Intensive versus Conventional Glucose Control in Critically Ill Patients

(2009)   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Intravenous Glucagon-Like Peptide-1 on Glucose Control and Hemodynamics After Coronary Artery Bypass Surgery in Patients With Type 2 Diabetes

(2008) Karsten Müssig et al.   AMERICAN JOURNAL OF CARDIOLOGY

The impact of delaying enteral feeding on gastric emptying, plasma cholecystokinin, and peptide YY concentrations in critically ill patients*

(2008) Nam Q. Nguyen et al.   CRITICAL CARE MEDICINE

Expression of taste molecules in the upper gastrointestinal tract in humans with and without type 2 diabetes

(2008) R L Young et al.   GUT

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

(2008) Daniel J Drucker et al.   LANCET

GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome

(2008) p. m. hellström et al.   NEUROGASTROENTEROLOGY AND MOTILITY

Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes

(2008) Helle Linnebjerg et al.   REGULATORY PEPTIDES